Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
ImmunoPrecise Antibodies Ltd is a biotechnology business based in the US. ImmunoPrecise Antibodies shares (IPA) are listed on the NASDAQ and all prices are listed in US Dollars. ImmunoPrecise Antibodies employs 73 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Guided Investing
Our top pick for
Experienced Investors
| Latest market close | $6.58 |
|---|---|
| 52-week range | $1.17 - $33.34 |
| 50-day moving average | $6.61 |
| 200-day moving average | $7.52 |
| Wall St. target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.46 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.58 from 2021-10-15
| 1 week (2021-10-08) | 8.40% |
|---|---|
| 1 month (2021-09-17) | -6.27% |
| 3 months (2021-07-16) | 21.18% |
| 6 months (2021-04-16) | -34.85% |
| 1 year (2020-10-16) | 271.75% |
|---|---|
| 2 years (2019-10-17) | 1,683.68% |
| 3 years (2018-10-17) | 814.40% |
| 5 years (2016-10-13) | N/A |
| Revenue TTM | $18.7 million |
|---|---|
| Gross profit TTM | $11.4 million |
| Return on assets TTM | -11.88% |
| Return on equity TTM | -26.6% |
| Profit margin | -53.49% |
| Book value | $2.88 |
| Market capitalisation | $127.4 million |
TTM: trailing 12 months
There are currently 448,182 ImmunoPrecise Antibodies shares held short by investors – that's known as ImmunoPrecise Antibodies's "short interest". This figure is 18.3% down from 548,823 last month.
There are a few different ways that this level of interest in shorting ImmunoPrecise Antibodies shares can be evaluated.
ImmunoPrecise Antibodies's "short interest ratio" (SIR) is the quantity of ImmunoPrecise Antibodies shares currently shorted divided by the average quantity of ImmunoPrecise Antibodies shares traded daily (recently around 101169.751693). ImmunoPrecise Antibodies's SIR currently stands at 4.43. In other words for every 100,000 ImmunoPrecise Antibodies shares traded daily on the market, roughly 4430 shares are currently held short.
To gain some more context, you can compare ImmunoPrecise Antibodies's short interest ratio against those of similar companies.
However ImmunoPrecise Antibodies's short interest can also be evaluated against the total number of ImmunoPrecise Antibodies shares, or, against the total number of tradable ImmunoPrecise Antibodies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ImmunoPrecise Antibodies's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 ImmunoPrecise Antibodies shares in existence, roughly 20 shares are currently held short) or 0.0258% of the tradable shares (for every 100,000 tradable ImmunoPrecise Antibodies shares, roughly 26 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ImmunoPrecise Antibodies.
Find out more about how you can short ImmunoPrecise Antibodies stock.
We're not expecting ImmunoPrecise Antibodies to pay a dividend over the next 12 months.
You may also wish to consider:
ImmunoPrecise Antibodies's shares were split on a 1:5 basis on 22 November 2020. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ImmunoPrecise Antibodies shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for ImmunoPrecise Antibodies shares which in turn could have impacted ImmunoPrecise Antibodies's share price.
Over the last 12 months, ImmunoPrecise Antibodies's shares have ranged in value from as little as $1.17 up to $33.34. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ImmunoPrecise Antibodies's is -0.1641. This would suggest that ImmunoPrecise Antibodies's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, ImmunoPrecise Antibodies has bucked the trend.
To put ImmunoPrecise Antibodies's beta into context you can compare it against those of similar companies.
ImmunoPrecise Antibodies Ltd. , together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has a research collaboration agreement with Pierre Fabre S. A for antibody discovery. ImmunoPrecise Antibodies Ltd.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.